Momenta, CSL in deal for Fc multimer proteins

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) gained $0.90 to $16.40 on Friday after it announced a license and option deal with CSL Ltd. (ASX:CSL) to develop Fc multimer proteins.

CSL will receive exclusive, worldwide rights to Momenta's M230, which is in preclinical development to treat autoimmune disorders. The partners expect to begin clinical testing of the selective immunomodulator of Fc receptors (SIF3) this year. The partners also intend to research and develop other Fc multimer programs...